FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
The reporting (5)
-
-
-
-
-
FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy BioSpace · 93d ago broke it first
The brief
- Velocity & Diffusion: Coverage escalated across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
FDA documents have raised concerns regarding the data for Capricor's therapy, deramiocel, leading to a sharp decline in CAPR stock. BioSpace reports that the FDA disputes the company's assertions of success in Phase 3 trials for the Duchenne muscular dystrophy (DMD) treatment.
Coverage from Yahoo Finance highlights a divide among analysts regarding the probability of the therapy's approval. Simultaneously, legal firms including Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics following the news.
Attention now turns to August 2026, the timeframe identified by RTTNews for the FDA's decision on biotech stocks including this therapy.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 92d ago.
Quick answers
What specific therapy is causing the controversy?
The therapy is deramiocel, a cell therapy intended for DMD.
How has the market responded to the FDA documents?
According to Yahoo Finance, CAPR stock is on track for its worst day ever.
When is the FDA's decision expected?
Coverage indicates a decision is expected in August 2026.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.